| 产品详情 |
| Edit |   |
|---|
| Product Name | GSK-3beta Inhibitor XXVII, CESI |
|---|
| Description | Purity ~96% (HPLC). A cell-permeable, 3-hydroxychromone derived compound that acts as a selective and reversible inhibitor of GSK-3beta (IC50 < 100nM). Shown to increase phosphorylation at Ser9. Does not show any inhibitory effect on a panel of 15 other protein kinases, including AMPK and Akt. By blocking GSK-3beta activity, it acts as a positive regulator of b-catenin signaling. Does not affect the viability or the growth rate of 3T3-L1 preadipocytes, however, it significantly reduces their differentiation into adipocytes (? 50 to 100nM). Exerts anti-adipogenic activity by down-regulating C/EBPa and PPARg. Shown to reduce adipocyte size and diminish weight gain in diet-induced obese mice without affecting their daily food intake. Primary Target: GSK3b Solubility: DMSO |
|---|
| Size | 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | GSK-3beta Inhibitor XXVII, CESI (2-(3-chloro-4-hydroxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-3-hydroxy-6-methyl-4H-chromen-4-one) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217405 |
|---|
| Price | |
|---|
| Order / More Info | GSK-3beta Inhibitor XXVII, CESI from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|